
Arielle Bryan, PhD
Market Development Manager – MDx and Enzymes
By using inhibitor-tolerant amplification enzymes, assay developers can design molecular diagnostics that deliver results faster.
Timely pathogen detection is essential for informing infectious disease management. The emergence of point-of-care (POC) molecular diagnostics has significantly improved turnaround time for pathogen detection applications.1 However, these methods depend on nucleic acid extraction, which adds time, cost, instruments and trained staff requirements.
The sample preparation challenge
Specimens such as blood, urine and saliva contain substances that interfere with nucleic acid amplification methods. Inhibition reduces sensitivity of an assay and can produce false negatives. Skipping nucleic acid extraction saves time and cost, but it also means inhibitors present in blood, saliva, urine and transport media are carried directly into the reaction.
Inhibitor-tolerant polymerases and reverse transcriptases are well-suited for working with crude, minimally processed samples. The ability to achieve highly sensitive amplification from crude samples allows assay developers to design diagnostics with simpler workflows and faster turnaround times.
Timely pathogen detection is essential for informing infectious disease management
Two routes to simpler workflows
Quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) assays with exceptional tolerance to clinically relevant inhibitors are well-suited for POC and central laboratory assays using qPCR instrumentation for quantitative or qualitative.
Inhibitor-tolerant recombinase polymerase amplification (RPA) is an ideal choice for field-based assays that require portable, low-power formats. It runs at a single temperature between 37–42°C and can produce detectable signals in 10 to 20 minutes with minimal instrumentation.2
Engineering for real-world challenges
At Watchmaker Genomics, we engineer inhibitor-tolerant qPCR, RT-qPCR and RPA enzymes for the challenging samples molecular diagnostics must tackle. From custom enzyme development and formulation optimisation to scalable manufacturing, we partner with assay developers to address application-specific challenges and simplify workflows, to help bring faster pathogen detection closer to the point of need.
[1] Poole S, Tanner AR, Naidu VV, et al. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: Results of a randomised controlled trial. J Infect. 2022; 85(6): 625–633.
[2] Daher RK, Stewart G, Boissinot M, Bergeron MG. Recombinase Polymerase Amplification for Diagnostic Applications. Clin Chem. 2016; 62(7): 947–958.
Global Cause